These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Astrocytoma (CNS WHO grade 4), IDH-mutant with co-occurrence of BRAF p.V600E mutation, and homozygous loss of CDKN2A. Leske H; Blakstad H; Lund-Iversen M; Skovholt EK; Niehusmann P; Ramm-Pettersen JT; Skogen K; Kongelf G; Sprauten M; Magelssen H; Brandal P Neuropathology; 2023 Oct; 43(5):385-390. PubMed ID: 36754566 [TBL] [Abstract][Full Text] [Related]
26. Novel insight into histological and molecular astrocytoma, IDH-mutant, Grade 4 by the updated WHO classification of central nervous system tumors. Chen W; Guo S; Wang Y; Shi Y; Guo X; Liu D; Li Y; Wang Y; Xing H; Xia Y; Li J; Wu J; Liang T; Wang H; Liu Q; Jin S; Qu T; Li H; Yang T; Zhang K; Wang Y; Ma W Cancer Med; 2023 Sep; 12(18):18666-18678. PubMed ID: 37667984 [TBL] [Abstract][Full Text] [Related]
27. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status. Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492 [TBL] [Abstract][Full Text] [Related]
28. Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes. Zhang Y; Lucas CG; Young JS; Morshed RA; McCoy L; Oberheim Bush NA; Taylor JW; Daras M; Butowski NA; Villanueva-Meyer JE; Cha S; Wrensch M; Wiencke JK; Lee JC; Pekmezci M; Phillips JJ; Perry A; Bollen AW; Aghi MK; Theodosopoulos P; Chang EF; Hervey-Jumper SL; Berger MS; Clarke JL; Chang SM; Molinaro AM; Solomon DA Neuro Oncol; 2022 Oct; 24(10):1749-1762. PubMed ID: 35395677 [TBL] [Abstract][Full Text] [Related]
29. Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma. Sabunga OD; Kaelan C; Zainuddin AA; Sungowati NK; Cangara MH; Miskad U Asian Pac J Cancer Prev; 2022 Sep; 23(9):3051-3059. PubMed ID: 36172668 [TBL] [Abstract][Full Text] [Related]
30. CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma. Yokoda RT; Cobb WS; Yong RL; Crary JF; Viapiano MS; Walker JM; Umphlett M; Tsankova NM; Richardson TE J Neuropathol Exp Neurol; 2023 Sep; 82(10):845-852. PubMed ID: 37550258 [TBL] [Abstract][Full Text] [Related]
31. Vascular differences between IDH-wildtype glioblastoma and astrocytoma IDH-mutant grade 4 at imaging and transcriptomic levels. Álvarez-Torres MDM; López-Cerdán A; Andreu Z; de la Iglesia Vayá M; Fuster-Garcia E; García-García F; García-Gómez JM NMR Biomed; 2023 Nov; 36(11):e5004. PubMed ID: 37482922 [TBL] [Abstract][Full Text] [Related]
32. Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort. Esteyrie V; Dehais C; Martin E; Carpentier C; Uro-Coste E; Figarella-Branger D; Bronniman C; Pouessel D; Ciron DL; Ducray F; Moyal EC; Network P Oncologist; 2021 May; 26(5):e838-e846. PubMed ID: 33524191 [TBL] [Abstract][Full Text] [Related]
33. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas. Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499 [TBL] [Abstract][Full Text] [Related]
34. Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification. Park YW; Kim S; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Kim SH; Lee SK; Chang JH Eur Radiol; 2024 Feb; 34(2):1376-1387. PubMed ID: 37608093 [TBL] [Abstract][Full Text] [Related]
35. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas. Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667 [TBL] [Abstract][Full Text] [Related]